Skip to content

Adhesive Tape Trauma Evaluation of Two Gentle Tapes

Adhesive Tape Trauma Evaluation of Two Gentle Tapes in Healthy Human Infant Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01354106
Enrollment
26
Registered
2011-05-16
Start date
2011-05-31
Completion date
2011-06-30
Last updated
2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive Tape Trauma

Keywords

Skin condition after wear

Brief summary

The objective of this study is to determine the relative gentleness of two tapes recognized for gentleness. A three-prong multidimensional evaluation consisting of laboratory assessments, expert skin grader and subject discomfort assessment will be used.

Detailed description

The objective of this study is to determine the relative gentleness of a new investigational tape compared to 3M Micropore tape, a gold standard tape recognized for its gentleness and used as a mainstay in cosmetic surgery and neonatal care. A three-prong multidimensional evaluation consisting of laboratory assessments, expert skin grader and subject discomfort assessment will be used.

Interventions

DEVICESkin Trauma

Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.

Sponsors

3M
CollaboratorINDUSTRY
Solventum US LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Months to 4 Years
Healthy volunteers
Yes

Inclusion criteria

1. Who are healthy and who have intact skin at the test site with a baseline score of 0 for erythema 2. Who are between the ages of 6 months - 4 years of age 3. Who has a Fitzpatrick Skin Type of I, II or III 4. Subject who's parent agrees to not use any products (i.e. topical medications, creams, powders or ointments) on the test sites for 24 hours prior to the study start date 5. Whose parent is willing to sign the Informed Consent Form.

Exclusion criteria

1. Who are known to be developmentally delayed 2. Who have sunburn, skin infection or scars, moles, or other blemishes on the back that would obscure grading of the test sites 3. Who have had any exposure to other topical medications, creams, powders, or ointments on the test sites 24 hours prior to the start of the study. 4. Who have had a strep infection within the past 2 weeks 5. Who have a history of diabetes, psoriasis, any active dermatitis, or recent history of dermatitis or skin reactions 6. Who have allergies to isocyanates, or acrylate adhesive products 7. Who currently take any antihistamines or anti-inflammatory medication or who have taken any of these medications within 48 hours prior to the start of the study or does not agree to refrain from taking these medications for the 48 hours prior to the start of the study and for the duration of the study (Tylenol is an acceptable pain reliever).

Design outcomes

Primary

MeasureTime frameDescription
Skin Trauma24 hoursExpert grader using Erythema/Edema Scale 0=No visible response 1. mild response 2. moderate response 3. severe response 4. extreme response

Countries

United States

Participant flow

Recruitment details

recruitment started May 16, 2011 at cyberDERM

Pre-assignment details

participant not to use any products on the test sites for 24 hours prior to the study state date.

Participants by arm

ArmCount
Infant
Investigational adhesive tape control paper tape
26
Total26

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicInfant
Age, Categorical
<=18 years
26 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Age, Continuous2.88 years
STANDARD_DEVIATION 0.87
Region of Enrollment
United States
26 participants
Sex: Female, Male
Female
13 Participants
Sex: Female, Male
Male
13 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 260 / 26
serious
Total, serious adverse events
0 / 260 / 26

Outcome results

Primary

Skin Trauma

Expert grader using Erythema/Edema Scale 0=No visible response 1. mild response 2. moderate response 3. severe response 4. extreme response

Time frame: 24 hours

ArmMeasureValue (MEAN)Dispersion
3M Kind Removal Silicone TapeSkin Trauma0.93 Units on a scaleStandard Deviation 0.14
3M Micropore Medical TapeSkin Trauma1.35 Units on a scaleStandard Deviation 0.11

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026